Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.25
GLAXF's Cash-to-Debt is ranked lower than
85% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. GLAXF: 0.25 )
Ranked among companies with meaningful Cash-to-Debt only.
GLAXF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.44 Max: 7.44
Current: 0.25
0.02
7.44
Equity-to-Asset 0.02
GLAXF's Equity-to-Asset is ranked lower than
97% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. GLAXF: 0.02 )
Ranked among companies with meaningful Equity-to-Asset only.
GLAXF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0  Med: 0.24 Max: 0.67
Current: 0.02
0
0.67
Debt-to-Equity 14.71
GLAXF's Debt-to-Equity is ranked lower than
100% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.30 vs. GLAXF: 14.71 )
Ranked among companies with meaningful Debt-to-Equity only.
GLAXF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07  Med: 1.36 Max: 140.3
Current: 14.71
0.07
140.3
Debt-to-EBITDA 2.73
GLAXF's Debt-to-EBITDA is ranked lower than
69% of the 503 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. GLAXF: 2.73 )
Ranked among companies with meaningful Debt-to-EBITDA only.
GLAXF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.17  Med: 1.97 Max: 4.26
Current: 2.73
1.17
4.26
Interest Coverage 5.65
GLAXF's Interest Coverage is ranked lower than
82% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 106.84 vs. GLAXF: 5.65 )
Ranked among companies with meaningful Interest Coverage only.
GLAXF' s Interest Coverage Range Over the Past 10 Years
Min: 3.71  Med: 9.74 Max: 17.51
Current: 5.65
3.71
17.51
Piotroski F-Score: 7
Altman Z-Score: 1.09
Beneish M-Score: -3.03
WACC vs ROIC
7.65%
17.48%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 13.84
GLAXF's Operating Margin % is ranked higher than
65% of the 781 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.94 vs. GLAXF: 13.84 )
Ranked among companies with meaningful Operating Margin % only.
GLAXF' s Operating Margin % Range Over the Past 10 Years
Min: 9.32  Med: 27.93 Max: 43.15
Current: 13.84
9.32
43.15
Net Margin % 7.75
GLAXF's Net Margin % is ranked higher than
51% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.12 vs. GLAXF: 7.75 )
Ranked among companies with meaningful Net Margin % only.
GLAXF' s Net Margin % Range Over the Past 10 Years
Min: 3.27  Med: 18.96 Max: 35.2
Current: 7.75
3.27
35.2
ROE % 229.78
GLAXF's ROE % is ranked higher than
100% of the 803 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.08 vs. GLAXF: 229.78 )
Ranked among companies with meaningful ROE % only.
GLAXF' s ROE % Range Over the Past 10 Years
Min: 17.3  Med: 58.26 Max: 229.78
Current: 229.78
17.3
229.78
ROA % 3.97
GLAXF's ROA % is ranked lower than
52% of the 831 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.77 vs. GLAXF: 3.97 )
Ranked among companies with meaningful ROA % only.
GLAXF' s ROA % Range Over the Past 10 Years
Min: 1.62  Med: 12.76 Max: 18.45
Current: 3.97
1.62
18.45
ROC (Joel Greenblatt) % 39.38
GLAXF's ROC (Joel Greenblatt) % is ranked higher than
78% of the 817 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.08 vs. GLAXF: 39.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GLAXF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 25.79  Med: 83.7 Max: 120.14
Current: 39.38
25.79
120.14
3-Year Revenue Growth Rate 1.80
GLAXF's 3-Year Revenue Growth Rate is ranked lower than
64% of the 674 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. GLAXF: 1.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GLAXF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -7.7  Med: 4.8 Max: 18.9
Current: 1.8
-7.7
18.9
3-Year EBITDA Growth Rate -20.50
GLAXF's 3-Year EBITDA Growth Rate is ranked lower than
89% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.20 vs. GLAXF: -20.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GLAXF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -20.5  Med: 7.9 Max: 21.7
Current: -20.5
-20.5
21.7
3-Year EPS without NRI Growth Rate -44.80
GLAXF's 3-Year EPS without NRI Growth Rate is ranked lower than
94% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. GLAXF: -44.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
GLAXF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -44.8  Med: 7.4 Max: 51.3
Current: -44.8
-44.8
51.3
GuruFocus has detected 3 Warning Signs with GlaxoSmithKline PLC GLAXF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GLAXF's 30-Y Financials

Financials (Next Earnings Date: 2018-02-08)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with GLAXF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:LSE:AZN, NYSE:LLY, NYSE:BMY, XTER:BAYN, XPAR:SAN, NYSE:ABBV, TSE:4503, TSE:4519, TSE:4578, NYSE:MRK, TSE:4568, TSE:4528, HKSE:01093, TSE:4151, MIL:REC, BOM:500087, BOM:500302, TSE:4536, SHSE:600436, SHSE:600867 » details
Traded in other countries:GSK.Argentina, GS7.Germany, GSK N.Mexico, GSK.Switzerland, GSK.UK, GSK.USA,
Headquarter Location:UK
GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including respiratory and antiviral, vaccines, over-the-counter (OTC) medicines and health-related consumer products.

In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by total sales. The company wields its might across multiple therapeutic classes, including respiratory and antiviral, as well as vaccines and healthcare-related consumer products.

Top Ranked Articles about GlaxoSmithKline PLC

Here's How Walmsley Just Completed a Clean Sweep at GlaxoSmithKline GlaxoSmithKline CEO Walmsley has had a great year this year. Here's how and why
When GlaxoSmithKline plc (NYSE:GSK) CEO Emma Walmsley took the helm at the company back in April this year, she was immediately thrust into the spotlight. She was tasked with helping GlaxoSmithKline overcome what many saw as a potentially major hurdle – bringing new drugs to market to limit the impact of a variety of legacy blockbusters reaching patent maturity and, in turn, suffering from generic competition. Read more...
Juluca® (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection
Adaptimmune Presents Study Designs for Ongoing MAGE-A4 and NY-ESO SPEAR T-cell Clinical Trials at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
NY-ESO Data Presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting Confirm Potential of Adaptimmune’s SPEAR T-Cell Therapy
Adaptimmune marks Official Opening of U.K. Headquarters
Adaptimmune Data to be Presented in an Oral Presentation and a Trial in Progress Poster at the Connective Tissue Oncology Society (CTOS) Annual Meeting
Adaptimmune to Present Two Trials in Progress Posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Avoiding Another Theranos How not to get gored by a unicorn
All founders dream of winning a place for themselves in investment history in their companies. Elizabeth Holmes, founder and CEO of Theranos, did just that at barely 30 years of age. Unfortunately for her and her company, that place happens to be among the rogues’ gallery including the likes of Enron and Lehman Brothers. Read more...
Stocks That Fell to 3-Year Lows in the Week of Oct. 27 The top four
GlaxoSmithKline PLC (NYSE:GSK), CVS Health Corp. (NYSE:CVS), Cardinal Health Inc. (NYSE:CAH), and Patterson Companies Inc. (NASDAQ:PDCO) have declined to their three-year lows. Read more...
CDC's Advisory Committee on Immunization Practices recommends Shingrix as the preferred vaccine for the prevention of shingles for adults aged 50 and up

Ratios

vs
industry
vs
history
PE Ratio 27.62
GLAXF's PE Ratio is ranked lower than
69% of the 570 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.41 vs. GLAXF: 27.62 )
Ranked among companies with meaningful PE Ratio only.
GLAXF' s PE Ratio Range Over the Past 10 Years
Min: 6.35  Med: 14.74 Max: 99999999.99
Current: 27.62
6.35
99999999.99
Forward PE Ratio 12.12
GLAXF's Forward PE Ratio is ranked higher than
73% of the 74 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.53 vs. GLAXF: 12.12 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 27.62
GLAXF's PE Ratio without NRI is ranked lower than
69% of the 566 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.56 vs. GLAXF: 27.62 )
Ranked among companies with meaningful PE Ratio without NRI only.
GLAXF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.38  Med: 14.68 Max: 284.83
Current: 27.62
6.38
284.83
Price-to-Owner-Earnings 9.38
GLAXF's Price-to-Owner-Earnings is ranked higher than
85% of the 310 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.43 vs. GLAXF: 9.38 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
GLAXF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.81  Med: 14.79 Max: 125.21
Current: 9.38
4.81
125.21
PB Ratio 49.35
GLAXF's PB Ratio is ranked lower than
99% of the 798 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. GLAXF: 49.35 )
Ranked among companies with meaningful PB Ratio only.
GLAXF' s PB Ratio Range Over the Past 10 Years
Min: 5.48  Med: 9.48 Max: 610.36
Current: 49.35
5.48
610.36
PS Ratio 2.12
GLAXF's PS Ratio is ranked higher than
55% of the 756 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.79 vs. GLAXF: 2.12 )
Ranked among companies with meaningful PS Ratio only.
GLAXF' s PS Ratio Range Over the Past 10 Years
Min: 1.94  Med: 2.75 Max: 3.68
Current: 2.12
1.94
3.68
Price-to-Free-Cash-Flow 13.48
GLAXF's Price-to-Free-Cash-Flow is ranked higher than
71% of the 212 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.72 vs. GLAXF: 13.48 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GLAXF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.24  Med: 16.42 Max: 136.91
Current: 13.48
8.24
136.91
Price-to-Operating-Cash-Flow 9.10
GLAXF's Price-to-Operating-Cash-Flow is ranked higher than
76% of the 290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.64 vs. GLAXF: 9.10 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GLAXF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.62  Med: 11.64 Max: 27.46
Current: 9.1
6.62
27.46
EV-to-EBIT 19.13
GLAXF's EV-to-EBIT is ranked lower than
63% of the 572 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.28 vs. GLAXF: 19.13 )
Ranked among companies with meaningful EV-to-EBIT only.
GLAXF' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.3  Med: 11 Max: 72.6
Current: 19.13
6.3
72.6
EV-to-EBITDA 11.66
GLAXF's EV-to-EBITDA is ranked higher than
55% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.61 vs. GLAXF: 11.66 )
Ranked among companies with meaningful EV-to-EBITDA only.
GLAXF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.6  Med: 9.25 Max: 35.2
Current: 11.66
5.6
35.2
EV-to-Revenue 2.69
GLAXF's EV-to-Revenue is ranked higher than
50% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.07 vs. GLAXF: 2.69 )
Ranked among companies with meaningful EV-to-Revenue only.
GLAXF' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.3  Med: 3.2 Max: 4
Current: 2.69
2.3
4
Shiller PE Ratio 14.18
GLAXF's Shiller PE Ratio is ranked higher than
86% of the 204 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.18 vs. GLAXF: 14.18 )
Ranked among companies with meaningful Shiller PE Ratio only.
GLAXF' s Shiller PE Ratio Range Over the Past 10 Years
Min: 11.57  Med: 15.1 Max: 20
Current: 14.18
11.57
20
Current Ratio 0.64
GLAXF's Current Ratio is ranked lower than
97% of the 738 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.53 vs. GLAXF: 0.64 )
Ranked among companies with meaningful Current Ratio only.
GLAXF' s Current Ratio Range Over the Past 10 Years
Min: 0.57  Med: 1.28 Max: 2.64
Current: 0.64
0.57
2.64
Quick Ratio 0.44
GLAXF's Quick Ratio is ranked lower than
97% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.94 vs. GLAXF: 0.44 )
Ranked among companies with meaningful Quick Ratio only.
GLAXF' s Quick Ratio Range Over the Past 10 Years
Min: 0.37  Med: 0.99 Max: 2.24
Current: 0.44
0.37
2.24
Days Inventory 193.61
GLAXF's Days Inventory is ranked lower than
81% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 120.98 vs. GLAXF: 193.61 )
Ranked among companies with meaningful Days Inventory only.
GLAXF' s Days Inventory Range Over the Past 10 Years
Min: 167.28  Med: 188.56 Max: 202.64
Current: 193.61
167.28
202.64
Days Sales Outstanding 81.52
GLAXF's Days Sales Outstanding is ranked lower than
54% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.92 vs. GLAXF: 81.52 )
Ranked among companies with meaningful Days Sales Outstanding only.
GLAXF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.62  Med: 59.8 Max: 93.9
Current: 81.52
54.62
93.9

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 5.78
GLAXF's Dividend Yield % is ranked higher than
95% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. GLAXF: 5.78 )
Ranked among companies with meaningful Dividend Yield % only.
GLAXF' s Dividend Yield % Range Over the Past 10 Years
Min: 3.23  Med: 4.94 Max: 6.24
Current: 5.78
3.23
6.24
Dividend Payout Ratio 1.69
GLAXF's Dividend Payout Ratio is ranked lower than
89% of the 416 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. GLAXF: 1.69 )
Ranked among companies with meaningful Dividend Payout Ratio only.
GLAXF' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.46  Med: 0.68 Max: 4.3
Current: 1.69
0.46
4.3
3-Year Dividend Growth Rate 1.30
GLAXF's 3-Year Dividend Growth Rate is ranked lower than
64% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. GLAXF: 1.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
GLAXF' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5.6 Max: 62.4
Current: 1.3
0
62.4
Forward Dividend Yield % 5.81
GLAXF's Forward Dividend Yield % is ranked higher than
94% of the 679 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.05 vs. GLAXF: 5.81 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 6.80
GLAXF's 5-Year Yield-on-Cost % is ranked higher than
91% of the 849 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.98 vs. GLAXF: 6.80 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
GLAXF' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 3.8  Med: 5.81 Max: 7.34
Current: 6.8
3.8
7.34
3-Year Average Share Buyback Ratio -0.30
GLAXF's 3-Year Average Share Buyback Ratio is ranked higher than
77% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. GLAXF: -0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GLAXF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -26.7  Med: -0.5 Max: 4.7
Current: -0.3
-26.7
4.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.88
GLAXF's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
53% of the 306 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.32 vs. GLAXF: 1.88 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GLAXF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.96  Med: 1.99 Max: 70.18
Current: 1.88
0.96
70.18
Price-to-Median-PS-Value 0.78
GLAXF's Price-to-Median-PS-Value is ranked higher than
65% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.04 vs. GLAXF: 0.78 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GLAXF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.63  Med: 1.19 Max: 3.4
Current: 0.78
0.63
3.4
Earnings Yield (Greenblatt) % 5.23
GLAXF's Earnings Yield (Greenblatt) % is ranked higher than
57% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.23 vs. GLAXF: 5.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GLAXF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.4  Med: 9.1 Max: 15.8
Current: 5.23
1.4
15.8
Forward Rate of Return (Yacktman) % -7.29
GLAXF's Forward Rate of Return (Yacktman) % is ranked lower than
86% of the 397 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.07 vs. GLAXF: -7.29 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
GLAXF' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -9.1  Med: 7.95 Max: 17.4
Current: -7.29
-9.1
17.4

More Statistics

Revenue (TTM) (Mil) $38,416.64
EPS (TTM) $ 0.61
Beta1.09
Short Percentage of Float0.00%
52-Week Range $17.00 - 22.35
Shares Outstanding (Mil)4,918.68

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 39,828 40,480 41,044
EPS ($) 1.44 1.43 1.51
EPS without NRI ($) 1.44 1.43 1.51
EPS Growth Rate
(Future 3Y To 5Y Estimate)
3.57%
Dividends per Share ($) 1.05 1.05 1.05

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}